Could Dendreon (biotech ticker: DNDN) be the next great small cap biotech in the pharma world of maga pharmaceuticals? There is a good article series by Mark Mitchell on Dendreon, a small cap Seattle based biotech, that has a flagship drug called Provenge, which is a novel prostate cancer treatment , but has revolutionary treatment approach, has to traverse paramount obstacles with the great hope in saving lives.
Dendreon recent run up of about 10% (closed at $26.4)in past two days with volume of approximately 21 millions on apparently no news. Could this surge be due to market adjustment of the stock or on anticipated news ? Well just have to wait and see. However, many speculates that Dendreon recent surged came from rumor of a buyout talk in Europe. Whichever may this be, I believe that Dendreon and it history has established itself to be huge force in the biotech market once their flagship drug Provenge get the approved from the FDA.
tag: DNDN,Provenge,Dendreon
Posts
I have heard a lot about dendreon in the news.
ReplyDelete